Translational Regenerative Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Region and Competition, 2020-2030F
세계 중개 재생의료 시장 규모는 2024년 34억 2,000만 달러에서 2030년에는 62억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 10.64%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.
중개 재생의료는 재생치료를 통해 손상되거나 질병에 걸린 조직이나 장기의 구조와 기능을 회복하거나 강화하는 데 초점을 맞춘 기초과학 연구와 임상 적용의 가교 역할을 하는 다학제적 영역입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
34억 2,000만 달러 |
| 시장 규모 : 2030년 |
62억 8,000만 달러 |
| CAGR : 2025-2030년 |
10.64% |
| 급성장 부문 |
종양학 |
| 최대 시장 |
북미 |
이 진화하는 분야는 기초 연구, 전임상, 임상시험, 그리고 최종적으로 의료 서비스 통합에 이르기까지 의료 혁신의 전체 파이프라인을 아우르는 분야입니다. 이 분야는 본질적으로 반복적이며, 임상적 통찰력을 연구에 피드백하여 치료 옵션을 지속적으로 개선하고 확장하고 있습니다. 심혈관 질환, 당뇨병, 신경 퇴행성 질환, 근골격계 질환과 같은 만성 질환의 유병률 증가와 세계 인구의 고령화는 첨단 재생치료에 대한 수요를 증가시키며 시장 성장을 가속하고 있습니다.
주요 시장 성장 촉진요인
재생의료의 기술 발전
주요 시장 이슈
제한된 환자 접근성 및 상환 장애물
지리적 위치, 사회경제적 지위, 보험 가입 여부에 따른 접근성 격차가 이러한 문제를 더욱 복잡하게 만들고 있으며, 공평한 의료 서비스 제공에 대한 우려가 커지고 있습니다.
주요 시장 동향
재생치료의 개인맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 제품 유형별(세포 유래 제품, 유전자 치료 제품, 조직공학 제품)
- 용도별(순환기과, 피부과, 당뇨병과, 신경과, 종양과, 정형외과)
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 북미의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제9장 남미의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 중재 재생의료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 중재 재생의료 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Astellas Pharma Inc.
- Athersys, Inc.
- AVITA Medical
- Axogen Corporation
- Gamida Cell Ltd.
- Integra LifeSciences Corporation
- Medtronic PLC
- Mesoblast Ltd.
- Novartis AG
- Spark Therapeutics, Inc.
제17장 전략적 제안
제18장 리서치사에 대해 & 면책사항
LSH
Global Translational Regenerative Medicine Market was valued at USD 3.42 billion in 2024 and is projected to reach USD 6.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.64% over the forecast period. Translational regenerative medicine represents a multidisciplinary domain bridging fundamental scientific research and clinical application, with a focus on restoring or enhancing the structure and function of damaged or diseased tissues and organs through regenerative therapies.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.42 Billion |
| Market Size 2030 | USD 6.28 Billion |
| CAGR 2025-2030 | 10.64% |
| Fastest Growing Segment | Oncology |
| Largest Market | North America |
This evolving field encompasses the entire medical innovation pipeline-from basic research and preclinical studies to clinical trials and eventual integration into healthcare practice. It is inherently iterative, with clinical insights feeding back into research to continually improve and expand therapeutic options. The rising prevalence of chronic conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and musculoskeletal ailments, along with an aging global population, is intensifying the demand for advanced, regenerative treatment alternatives-thereby driving market growth.
Key Market Drivers
Technological Advancements in Regenerative Medicine
Breakthrough technologies are reshaping regenerative medicine, unlocking transformative opportunities for treatment development across a spectrum of medical conditions. One notable advancement is 3D bioprinting, which enables the precise layer-by-layer construction of tissues and organs using biomaterials, living cells, and growth factors. This innovation supports the creation of tailor-made tissues and holds promise for organ transplantation and tissue regeneration.
Gene-editing technologies, particularly CRISPR-Cas9, have revolutionized the ability to modify genetic material with high precision. These tools facilitate the correction of genetic mutations, the engineering of therapeutic cells, and the development of targeted gene therapies.
Another key development is induced pluripotent stem cell (iPSC) technology, which allows adult cells to be reprogrammed into a pluripotent state. iPSCs can be differentiated into any cell type and used to create personalized cell lines for disease modeling, drug testing, and patient-specific treatments-minimizing immune rejection and enhancing clinical efficacy.
Key Market Challenges
Limited Patient Access and Reimbursement Hurdles
Access to regenerative therapies remains a significant challenge due to the high costs associated with research, development, and administration. Many treatments-such as stem cell and gene therapies-are expensive and may not be fully covered by insurance providers, who often classify these therapies as experimental or investigational. As a result, patients may face substantial out-of-pocket expenses.
The reimbursement framework for regenerative medicine is still in a developmental phase, with considerable variation across regions and healthcare systems. This inconsistency creates uncertainty for providers and patients alike. Furthermore, the regulatory approval process for regenerative therapies is often lengthy and complex, delaying patient access, particularly in urgent medical cases.
In many instances, regenerative therapies lack extensive long-term data on safety and efficacy, which can influence payer confidence and slow reimbursement decisions. Administrative requirements such as prior authorizations can also introduce delays, while healthcare providers may face operational challenges due to insufficient infrastructure or experience in managing reimbursement for advanced therapies.
Disparities in access based on geographic location, socioeconomic status, and insurance availability further compound these challenges, raising concerns about equitable healthcare delivery.
Key Market Trends
Personalized Medicine in Regenerative Therapies
Personalized medicine is emerging as a transformative trend within regenerative medicine, enabling the development of highly tailored treatments based on an individual's genetic and cellular profile. Technologies such as iPSCs derived from a patient's own cells are being used to generate specific cell types for targeted therapy. This approach reduces the risk of immune rejection and enhances therapeutic effectiveness.
Genomic data is increasingly used to guide treatment selection. Genetic testing can identify mutations or polymorphisms that impact a patient's response to certain therapies, allowing clinicians to choose the most appropriate regenerative treatment strategies.
Moreover, patient-specific disease models, developed using iPSCs, provide valuable insights into disease mechanisms, supporting the development of personalized drug regimens and regenerative protocols. Customized dosage, treatment timing, and delivery methods are optimized based on individual health profiles, which can improve therapeutic outcomes and minimize adverse effects.
In oncology, personalized regenerative approaches are driving innovation in cancer immunotherapy. Autologous therapies such as CAR-T cell therapy involve modifying a patient's own immune cells to recognize and combat cancer. These treatments are customized according to the patient's cancer subtype and genetic makeup.
Personalized medicine also emphasizes ongoing monitoring, utilizing biomarkers and genomic data to assess therapeutic response in real-time, enabling dynamic adjustments to treatment plans and ensuring optimal patient outcomes.
Key Market Players
- Astellas Pharma Inc.
- Athersys, Inc.
- AVITA Medical
- Axogen Corporation
- Gamida Cell Ltd.
- Integra LifeSciences Corporation
- Medtronic PLC
- Mesoblast Ltd.
- Novartis AG
- Spark Therapeutics Inc.
Report Scope:
In this report, the Global Translational Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Translational Regenerative Medicine Market, By Product Type:
- Cell Based Product
- Gene Therapy Product
- Tissue Engineered Product
Translational Regenerative Medicine Market, By Application:
- Cardiovascular
- Dermatology
- Diabetes
- Neurology
- Oncology
- Orthopedic
Translational Regenerative Medicine Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Translational Regenerative Medicine Market.
Available Customizations:
Global Translational Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Translational Regenerative Medicine Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product Type (Cell Based Product, Gene Therapy Product, Tissue Engineered Product)
- 5.2.2. By Application (Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Orthopedic)
- 5.2.3. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Translational Regenerative Medicine Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Application
- 6.2.3. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Translational Regenerative Medicine Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product Type
- 6.3.1.2.2. By Application
- 6.3.2. India Translational Regenerative Medicine Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product Type
- 6.3.2.2.2. By Application
- 6.3.3. Australia Translational Regenerative Medicine Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product Type
- 6.3.3.2.2. By Application
- 6.3.4. Japan Translational Regenerative Medicine Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Product Type
- 6.3.4.2.2. By Application
- 6.3.5. South Korea Translational Regenerative Medicine Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Product Type
- 6.3.5.2.2. By Application
7. Europe Translational Regenerative Medicine Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Application
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Translational Regenerative Medicine Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product Type
- 7.3.1.2.2. By Application
- 7.3.2. Germany Translational Regenerative Medicine Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product Type
- 7.3.2.2.2. By Application
- 7.3.3. Spain Translational Regenerative Medicine Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product Type
- 7.3.3.2.2. By Application
- 7.3.4. Italy Translational Regenerative Medicine Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product Type
- 7.3.4.2.2. By Application
- 7.3.5. United Kingdom Translational Regenerative Medicine Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product Type
- 7.3.5.2.2. By Application
8. North America Translational Regenerative Medicine Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Application
- 8.2.3. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Translational Regenerative Medicine Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product Type
- 8.3.1.2.2. By Application
- 8.3.2. Mexico Translational Regenerative Medicine Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product Type
- 8.3.2.2.2. By Application
- 8.3.3. Canada Translational Regenerative Medicine Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product Type
- 8.3.3.2.2. By Application
9. South America Translational Regenerative Medicine Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Application
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Translational Regenerative Medicine Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product Type
- 9.3.1.2.2. By Application
- 9.3.2. Argentina Translational Regenerative Medicine Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product Type
- 9.3.2.2.2. By Application
- 9.3.3. Colombia Translational Regenerative Medicine Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product Type
- 9.3.3.2.2. By Application
10. Middle East and Africa Translational Regenerative Medicine Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Application
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Translational Regenerative Medicine Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product Type
- 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Translational Regenerative Medicine Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product Type
- 10.3.2.2.2. By Application
- 10.3.3. UAE Translational Regenerative Medicine Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product Type
- 10.3.3.2.2. By Application
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Translational Regenerative Medicine Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Astellas Pharma Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Athersys, Inc.
- 16.3. AVITA Medical
- 16.4. Axogen Corporation
- 16.5. Gamida Cell Ltd.
- 16.6. Integra LifeSciences Corporation
- 16.7. Medtronic PLC
- 16.8. Mesoblast Ltd.
- 16.9. Novartis AG
- 16.10. Spark Therapeutics, Inc.
17. Strategic Recommendations
18. About Us & Disclaimer
